

15:07 13 Aug 2019

## VolitionRx reports strong second quarter as it moves forward on key MoUs

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds caught up with Proactive London's Andrew Scott to discuss the group's second quarter update.

Reynolds says they've continued to strengthen the balance sheet with cash and cash equivalents increasing significantly thanks to warrant exercises by investors.

He adds they're now looking to advance the previously announced large-scale colorectal cancer trials in Europe, the US and Asia as well as the clinical trial program for lung cancer.

**Price:** US\$4.2

**Market Cap:** US\$171756000M

### 1 Year Share Price Graph



August 2018 February 2019 August 2019

### Share Information

**Code:** VNRX

**Listing:** NYSEMKT

52 week	High	Low
	\$4.65	\$1.67

**Sector:** Pharma & Biotech

**Website:** volitionrx.com

### Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. &nbsp;.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.